📋 Tender Overview
Siemens end-to-end, AI-enabled digital twin portfolio connect development, production, infrastructure and operations, from molecule to market
In a vaccine development engagement, Siemens and Atos helped GSK cut physical experiments by 25 percent using digital twin technology
Following its 2025 acquisition of Dotmatics, Siemens is extending AI-powered digital twin capabilities into drug discovery
Siemens today announced that IDC MarketScape has named it a Leader in its 2026 assessment of life sciences R&D lab technology and consulting providers. The recognition appears in the IDC MarketScape: Worldwide Life Sciences R&D Lab of the Future Technology Solutions and Consulting Services 2026 Vendor Assessment1. The recognition comes as life sciences companies face mounting pressure to modernize fragmented lab systems while meeting increasingly complex regulatory requirements.
Siemens portfolio for the life sciences industry spans the pharmaceutical value chain from R&D through manufacturing.
IDC MarketScape assessed vendors based on their current capabilities and the strength of their strategy for the next three to five years. According to the report, Siemens differentiators include its end-to-end coverage of the pharma value chain, from R&D, pilot, scale-up through commercial manufacturing to buildings and electrification, its comprehensive digital twin and AI-enabled portfolio, its open and vendor-agnostic Smart Lab Ecosystem, and its Enterprise Recipe Management approach built on the ISA-88 standard.
Life sciences companies no longer need isolated digital transformation initiatives. They need a continuous digital thread that connects scientific discovery, process development and manufacturing execution, said Maria Grahm, Vice President of Vertical Life Sciences at Siemens. We believe this recognition validates Siemens vision of creating a seamless, AI-enabled environment where insights generated in the lab can directly accelerate industrial-scale production and ultimately help bring therapies to patients faster. Siemens defines the Lab of the Future as a connected, AI-enabled scientific environment where data, models and workflows move seamlessly across discovery, development, scale-up and manufacturing.
As the IDC MarketScape notes, GSK worked with Siemens and Atos to digitalize its vaccine development and manufacturing value chain, using AI, SIMATIC SIPAT, TIA Portal, and Simcenter to virtually test and gain insights across development and production and to build predictive and prescriptive models from real-time, inline sensor data. Siemens noted that the engagement produced a digital twin for adjuvant technologies that reduced physical experiments by 25 percent, alongside a double-digit percentage reduction in batches and a shortened time to market for a new process.
In another engagement noted in the report, AstraZeneca worked with Siemens gPROMS-formulated products process modeling technology to explore the design of a tablet manufacturing process, constructing a flowsheet model of a dry granulation and tableting process and running over 3,000 virtual experiments to quantify the criticality of material properties and process parameters on product quality attributes, generating significant savings in time, resources, and materials versus physical experimentation.
The report also noted several strengths, noting Siemens Smart Lab Ecosystem (SLE), a modular, vendor-agnostic infrastructure kit that allows flexible plug -and-play composition of room segments, devices, and sensors to create adaptable research and laboratory spaces. Independently tested with the University of Applied Sciences Luzern in Switzerland under Project PEARL, Siemens reports the Smart Lab Ecosystem delivers a 31 percent superior local air change rate, 29 percent faster particle removal, and 45 percent better ventilation efficiency, alongside up to 60 percent faster lab design and construction and up to 80 percent reduction in changeover time between lab configurations.
These engagements build on Siemens broader AI strategy for life sciences. Following its 2025 acquisition of Dotmatics, Siemens extended its digital thread further upstream into drug discovery, creating a unique connection between scientific research and industrial execution. Through Dotmatics Luma, an AI-native scientific intelligence platform, researchers can connect laboratory instruments, scientific applications and enterprise systems into a unified data environment that supports faster and more informed decisions throughout the product lifecycle. Dotmatics Luma is part of Siemens Xcelerator, Siemens open digital business platform that unifies its life sciences offering across the value chain. Siemens portfolio for the life sciences industry spans the entire pharmaceutical value chain, from molecule to market, enabling a continuous digital thread across product and production lifecycles.
About IDC MarketScape
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each suppliers position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.
1 IDC MarketScape: IDC MarketScape: Worldwide Life Sciences R&D Lab of the Future Technology Solutions and Consulting Services 2026 (Doc #US54122126, August 2026).